We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+50.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$1.1B
AUM Growth
+$345M
Cap. Flow
+$47.4M
Cap. Flow %
4.29%
Top 10 Hldgs %
64.76%
Holding
67
New
13
Increased
15
Reduced
13
Closed
9
Avg Time Held Equity + Options
6.4 quarters
Top 10 Avg Time Held Equity + Options
4.4 quarters
Top 20 Avg Time Held Equity + Options
6.1 quarters
Avg Time Held Equity only
6.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
6.1 quarters

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$29.8M
2
IMMX icon
Immix Biopharma
IMMX
+$21.8M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$14.2M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$14.1M
5
VSTM icon
Verastem
VSTM
+$8.71M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$19.5M
2
HROW icon
Harrow
HROW
+$16.1M
3
SNWV icon
SANUWAVE Health Inc
SNWV
+$10.5M
4
JBIO icon
Jade Biosciences
JBIO
+$5.89M
5
LQDA icon
Liquidia Corp
LQDA
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGON icon
51
CG Oncology
CGON
$5.53B
$1.26M 0.11%
17,789
-77,011
-81% -$5.03M
2025 Q1
5 quarters
BHVN icon
52
Biohaven
BHVN
$1.72B
$1.16M 0.11%
+77,915
New +$839K
2026 Q2
0 quarters
AVIR icon
53
Atea Pharmaceuticals
AVIR
$399M
$1.09M 0.1%
235,000
-87,600
-27% -$436K
2025 Q4
2 quarters
KTTA icon
54
Pasithea Therapeutics
KTTA
$14.2M
$1.06M 0.1%
+2,050,000
New +$1.41M
2026 Q2
0 quarters
ADCT icon
55
ADC Therapeutics
ADCT
$217M
$749K 0.07%
+700,000
New +$2.04M
2026 Q2
0 quarters
OKYO icon
56
OKYO Pharma
OKYO
$75.6M
$563K 0.05%
+375,204
New +$601K
2026 Q2
0 quarters
PTN icon
57
Palatin Technologies
PTN
$14.6M
$221K 0.02%
+20,500
New +$338K
2026 Q2
0 quarters
ADGM icon
58
Adagio Medical Holdings
ADGM
$3.41M
$13.4K ﹤0.01%
18,444
– –
2024 Q3
7 quarters
ASRT icon
59
DELISTED
Assertio
ASRT
– –
-265,707
Closed -$5.06M –
CATX icon
60
CALL
Perspective Therapeutics
CATX
$259M
– –
-200,000
Closed -$834K –
CATX icon
61
Perspective Therapeutics
CATX
$259M
– –
-4,675,000
Closed -$19.5M –
NXTC icon
62
NextCure
NXTC
$28.7M
– –
-141,181
Closed -$1.51M –
PLX icon
63
Protalix BioTherapeutics
PLX
$222M
– –
-340,000
Closed -$738K –
RIGL icon
64
Rigel Pharmaceuticals
RIGL
$881M
– –
-70,000
Closed -$1.89M –
STRO icon
65
Sutro Biopharma
STRO
$183M
– –
-190,671
Closed -$4.75M –
TECX icon
66
Tectonic Therapeutic
TECX
$417M
– –
-123,000
Closed -$3.8M –
LBRX icon
67
LB Pharmaceuticals
LBRX
$1.12B
– –
-14,506
Closed -$358K –
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2026 Portfolio in Review

As of Q2 2026, Opaleye Management held 67 positions worth $1.1B, up 45% from $759M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $47.4M of net new capital in Q2 2026, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Immix Biopharma: 2,345,000 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Harrow, an estimated $16.1M trimmed.

  • Opaleye Management's largest Q2 2026 buy was Immix Biopharma: 2,345,000 shares worth $24.2M.
  • Opaleye Management added most to Disc Medicine in Q2 2026, an estimated $29.8M increase.
  • Opaleye Management's biggest Q2 2026 reduction was Harrow, cutting an estimated $16.1M.
  • Opaleye Management fully exited Perspective Therapeutics in Q2 2026, selling an estimated $19.5M.
  • Opaleye Management's ten largest holdings make up 65% of its $1.1B portfolio in Q2 2026.
  • Opaleye Management opened 13 new positions and closed 9 in Q2 2026.
  • Opaleye Management's portfolio value rose 45% quarter-over-quarter to $1.1B.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.